Tag: time

Reports Adjusted EBITDAS of $9.6 million, representing a 16% improvement from prior year

EDINBURG, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Shenandoah Telecommunications Company (“Shentel” or the “Company”) (Nasdaq: SHEN) announced today that its Board of Directors has appointed Edward H. “Ed” McKay as President and Chief Executive Officer (“CEO”). Christopher E. French, Shentel’s current President and CEO, will step into the role of Executive Chairman of the Board and remain active in steering the Company’s strategy while continuing to work closely with the senior leadership team and the Board of Directors. The transition date for both executives is expected to be September 1, 2025.

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating UY Scuti Acquisition Corp. (NASDAQ: UYSC) related to its merger with Isdera Group Limited. Upon completion of the proposed transaction, each outstanding UY ordinary share will be converted automatically into a one Class A Ordinary Share of the combined company. Is it a fair deal?

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

PENNSAUKEN, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT) will hold a conference call on Thursday, August 7, 2025 at 11:30 a.m. Eastern time to discuss the financial results for the thirteen and twenty-six weeks ended June 28, 2025. The teleconference dial-in numbers are (888) 272-8703 for domestic callers and (713) 936-6995 for international callers.